辉瑞新冠药副作用有哪些？

What are there

Common side effects of Pfizer's new coronavirus drug nematvir/ritonavir (Paxlovid) include diarrhea and taste disturbance, and some rare side effects include indigestion, gastroesophageal reflux disease, vomiting, myalgia, dizziness, increased alanine aminotransferase (ALT), and increased aspartate aminotransferase (AST). In addition, there are relatively rare side effects such as aphthous ulcer, colitis, dry mouth, loose stool, chest discomfort, loss of appetite, headache, abnormal sense of smell, anxiety, dyspnea, hiccup, oropharyngeal pain, maculopapular rash, skin exfoliation, decreased blood thyroid stimulating hormone (TSH), etc.

Adverse reactions in Pfizer's new coronavirus drug trial

Pfizer's new coronavirus drug Nematvir/Ritonavir (Paxlovid) is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and are at increased risk of developing severe COVID-19 disease. Adverse reactions were listed in the trials. It is recommended that patients pay attention to their physical reactions during medication. If they are intolerant, they should contact their doctor in time for symptomatic treatment.

In the Phase II/III, randomized, double-blind, placebo-controlled C4671005 study (EPIC-HR study) in non-hospitalized adult subjects with laboratory-confirmed novel coronavirus (SARS-CoV-2) infection, a total of 2,224 adult subjects with novel coronavirus pneumonia (COVID-19) at high risk of progression to severe disease received at least one dose of nematvir/ritonavir 300 mg/100 mg, 1,109 people) or placebo (1,115 people). Study drug was administered every 12 hours for 5 days.

Compared with the placebo group, the frequency of adverse events in the Pfizer new coronavirus drug nematvir/ritonavir (Paxlovid) group increased by 1% (≥ 5 subject differences). They were dysgeusia (6% and <1%), diarrhea (3% and 2%), hypertension (1% and <1%), and myalgia (1% and <1%). The proportion of subjects who discontinued treatment due to adverse events was 2% in the Pfizer new crown drug nematvir/ritonavir (Paxlovid) group and 4% in the placebo group.

Recommended related articles: